| Document Date: 2013-02-14 16:20:43
Open Document File Size: 63,24 KBShare Result on Facebook
City Irvine / / Company Allergan Inc. / Structural Formula CH3 CH3 H CO / / Country United States / / IndustryTerm longterm local corticosteroid applications / long-term applications / / MedicalCondition glaucoma / inflammatory response / Patients If inflammation / scar / craniorachischisis / Keratitis / corticosteroid-responsive inflammation / acute anterior uveitis / spina bifida / conjunctival hyperemia / secondary ocular infections / ocular irritation / Carcinogenesis / ocular diseases / herpes / posterior subcapsular cataract / Fungal and viral infections / erythema / mydriasis / viral infections / viral diseases / dendritic keratitis / eye pruritus / conjunctivitis / pain / epithelial herpes simplex keratitis / cleft palate / mycobacterial infection / encephalocele / allergic reactions / suspected hypersensitivity / eye pain / bleb formation / infection / Acute purulent infections / inflammation / vaccinia / rash / varicella / eye diseases / cataract / fungal infections / fungal diseases / secondary ocular infection / chronic conditions / / MedicalTreatment cataract surgery / / Position PRECAUTIONS General / physician / / Product dexamethasone / edetate disodium / sodium chloride / FML FORTE / / ProvinceOrState California / /
SocialTag |
NDA[removed]S-025 Page 3 FML FORTE® (fluorometholone ophthalmic suspension, USP) 0.25%